{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"651.122","value":"878.75"},{"groupId":"OG001","spread":"194.841","value":"849.00"}]}],"title":"Cmin,ss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"812.63","value":"1585.5"},{"groupId":"OG001","spread":"261.02","value":"1606.7"}]}],"title":"Cmax,ss"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Niraparib 200 milligrams (mg) orally once daily from Days 1 to 21 and Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 1: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants received Niraparib 300 mg orally once daily from Days 1 to 21 and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 1: Niraparib 300 mg + Pembrolizumab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic Analysis Set. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 2 Day 1 (each cycle of 21 days)","title":"Phase 1: Minimum Observed Plasma Concentration at Steady State (Cmin,ss) and Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Niraparib","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}